​Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth is a new market research publication announced by Reportstack. Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%). As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. 

Throughout the forecast period, the global Prostate Cancer (PC) market is expected to increase from $7.6 billion in 2014 to $13.6 billion by 2021. Because the impact of novel therapies is likely to be minimal, this growth will be driven predominantly by the forecast growth in disease prevalence. PC is a disease of the elderly, with approximately 70% of cases diagnosed in men above the age of 65. It is estimated that by 2030, the proportion of men aged 65 and over will increase to 20-30% in the territories analyzed in this report, from an estimated 13-20% in 2010. As a result, the aging population will have a significant impact on the number of diagnoses during the forecast period. The result is an increase in the prevalence population from 2.97 billion in 2014 to 3.36 billion in 2021, with the resulting 134,500 increase in the treatment population having a significant impact on market growth.

To access full report with TOC, please visit Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth.

Scope

Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.

What factors are driving the market growth?

How can the factors limiting growth be overcome in the future?

The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.

What other gaps in the market are being addressed by the current pipeline dynamics?

The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.

What are the dynamics of the remaining 50% of the pipeline?

How does this reflect the need for novel targeted therapies?

There has been a significant shift away from hormonal therapies. Key mechanisms of action across the pipeline include cancer immunotherapies against PSMA, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.

Reasons To Buy

This report will allow you to:

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.

Visualize the composition of the PC market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.

Analyze the PC pipeline and stratify by stage of development, molecule type, and molecular target.

Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.

Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the AML market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.

Identify commercial opportunities in the PC deals landscape by analyzing trends in licensing and co-development deals.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

​Reportstack Market Research

###